Synchron
Synchron develops the Stentrode™, a minimally invasive brain-computer interface that allows paralyzed patients to control digital devices with their thoughts.
Secondary Market Price
How Synchron Measures Up
To help you manage your Synchron equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Synchron's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Synchron Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Synchron's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Synchron is a medical equipment company developing implantable neurotechnology, specifically a brain-computer interface (BCI) called the Stentrode™. This device is designed to help people with severe paralysis restore their ability to communicate and interact with digital devices through thought. The company's approach is minimally invasive, implanting the device through the jugular vein to reach the brain's motor cortex, which avoids the need for open-brain surgery. Synchron was founded in 2016 by neurologist Thomas Oxley and is currently conducting clinical studies, such as the COMMAND trial, with patients using the technology. The company is headquartered in Brooklyn, New York, with an additional location in Melbourne, Australia.
Looking forward, Synchron is focused on scaling its operations and accelerating the commercialization of its BCI technology, with the goal of making it available in standard hospitals. The company's progress has been supported by a recent $200 million Series D funding round, with investors including Khosla Ventures and Bezos Expeditions. This funding is intended to expand operations and further develop the technology. Recent media coverage has highlighted the company's work, including a feature in TIME Magazine and a CBS Evening News segment that showed a clinical trial participant using the Synchron BCI to operate a digital device.
- Double Point Ventures
- ARCH Venture Partners
- Khosla Ventures
- Bezos Expeditions
- NeuroTechnology Investors
- METIS
- Australian National Reconstruction Fund
- T.Rx Capital
- Qatar Investment Authority
- K5 Global
- Protocol Labs
- IQT
- Gates Frontier
- Reliance Digital Health Limited
- Greenoaks
- Alumni Ventures
- Moore Strategic Ventures
- Project X
- Forepont Capital Partners
- ID8 Investments
- Shanda Group
- University of Melbourne
- Co-Founder, Tom Oxley
- Co-Founder, Nick Opie
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Synchron worth joining?
Deciding if a company is worth joining depends on your personal career goals and your belief in the company's long-term potential. A platform like Prospect can help you forecast the value of your potential equity compensation to make a more informed financial decision.
What should I do with my Synchron stock?
Managing private company stock involves complex tax and financial planning, including deciding when to exercise options or sell shares. Tools from Prospect offer personalized, tax-optimized strategies and allow you to model different financial scenarios with your equity.
Can you sell Synchron stock?
As Synchron is a private company, selling stock is typically possible through secondary markets or company-approved tender offers, though it is less liquid than public stock. Prospect provides tools and access to secondary market pricing to help you navigate selling opportunities and identify which shares to sell for tax advantages.
How can I find the value of my Synchron stock?
The value of private stock is determined by internal 409A valuations, recent funding rounds, and secondary market trades, not a public market price. You can use Prospect’s predictive models, which are trained on data used by top VCs, to forecast the potential future value of your shares.
What is Synchron's equity worth?
The precise worth of Synchron's equity fluctuates and is not publicly listed, but it can be estimated based on the company's latest valuation and performance. To get a personalized forecast for your holdings, Prospect offers proprietary models to project your equity's potential value.
What is Synchron's stock ticker symbol?
Since Synchron is a private company and not traded on a public stock exchange, it does not have a stock ticker symbol. Ticker symbols are assigned only when a company completes an Initial Public Offering (IPO) and lists on an exchange.
Can I buy or sell Synchron stock?
Selling private stock like Synchron's is sometimes possible through secondary markets or tender offers, while buying is typically restricted to accredited investors or employees. Platforms like Prospect can help employees manage their existing equity and navigate selling opportunities with tax-optimized strategies.
What is the criteria to buy or invest in Synchron stock?
Investing in a private company like Synchron is generally limited to institutional investors and accredited investors who meet specific income or net worth requirements. Employees may receive equity as compensation and can use platforms like Prospect to manage and optimize its value.
